Back to Journals » ImmunoTargets and Therapy » Volume 7

Multiple effects of CD40–CD40L axis in immunity against infection and cancer

Authors Ara A, Ahmed KA, Xiang J

Received 24 January 2018

Accepted for publication 8 March 2018

Published 28 June 2018 Volume 2018:7 Pages 55—61


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Michael Shurin

Anjuman Ara,1,2 Khawaja Ashfaque Ahmed,1,2 Jim Xiang1,2

1Cancer Research Cluster, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada; 2Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Abstract: CD8+ cytotoxic T lymphocyte (CTL) protects against infection and cancer cells. Understanding the mechanisms involved in generation and maintenance of effective CTL responses is essential for improving disease therapy and vaccine protocols. During CTL responses, immune cells encounter several tightly regulated signaling pathways; therefore, in such a dynamic process, proper integration of critical signals is necessary to orchestrate an effective immune response. In this review, we have focused on CD40–CD40L interactions (a key signal) in the regulation of dendritic cell (DC)–T cell (CD4+ T and CD8+ T) cross-talk, rescuing CTL exhaustion, and converting DC tolerization. We have also highlighted the knowledge gap and future directions to design immunotherapies.

Keywords: CD40–CD40L, costimulatory signals, T-cell immunity, CTL exhaustion, mTORC1, trogocytosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]